ipodate
Trade name: Oragrafin
Approved
Mar 15, 1962
Iopanoic acid and ipodate salts have been used for oral cholangiography to visualize the biliary ducts. Ipodate salts have been used for the long-term treatment of Graves' disease and in hyperthyroidism. Ipodate reduced levels of T3 and T4 in the patients. Ipodate also inhibits the conversion of T4 to T3. It is not considered a first-line approach. Ipodate sodium lacks FDA approval for these uses. During investigation of mechanism of action was discovered, that binding of sodium ipodate with nuclear T3 receptors was not a prominent mechanism via which the drug attenuates T3 effects in vivo. Sodium ipodate could enhance T3 effects at the cellular level and that enhancement could not be reflected by routinely monitored serum TSH. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Timeline
Indications
Mechanism of action
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedMar 15, 1962
Chemistry & pharmacology
SMILES
CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I- Mol. weight
- 597.9572 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaIpodate sodium ↗
- NCATSF604ZKI910 ↗
- ChEMBLCHEMBL2068725 ↗
- ChEMBLCHEMBL1201243 ↗
- ChEMBLCHEMBL1201033 ↗
Also known as
- bilimin acid
- bilivist
- bilivist
- bilopten
- calcium iopodate
- calcium iopodate
- calcium iopodate
- iopodic acid
- iopodic acid
- iopodic acid
- iopodic acid
- ipodate
- ipodate
- ipodate
- ipodate
- ipodate
- ipodate
- ipodate
- ipodate calcium
- ipodate calcium
- ipodate calcium
- ipodate calcium
- ipodate sodium
- ipodate sodium
- ipodate sodium
- ipodate sodium
- oragrafin
- oragrafin
- oragrafin
- oragrafin calcium
- oragrafin calcium
- oragrafin sodium
- oragrafin sodium
- oragrafin sodium
- sodium iopodate
- sodium iopodate
- sodium iopodate
- sodium ipodate
- sodium ipodate